Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydrocortisone acetate + bacitracin zinc + neomycin sulfate + polymyxin b is a topical ophthalmic combination drug formulated as a sterile ointment for steroid-responsive inflammatory ocular conditions in which bacterial infection is present or there is a risk of bacterial infection. The product combines three antibacterial small molecules with a corticosteroid: bacitracin inhibits bacterial cell wall synthesis, polymyxin b disrupts bacterial cell membrane permeability, neomycin inhibits bacterial protein synthesis by binding the bacterial 30S ribosomal subunit, and hydrocortisone acetate activates the glucocorticoid receptor to suppress ocular inflammation. It is used for inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, including chronic anterior uveitis, conjunctivitis, and corneal injury from chemical, thermal, or radiation burns or foreign body penetration. It is marketed in the United States as Neo-Polycin HC and is also available as a generic ophthalmic ointment from multiple manufacturers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydrocortisone acetate + bacitracin zinc + neomycin sulfate + polymyxin b.